Status:

COMPLETED

Pemetrexed/Carboplatin Non-Small Cell Lung Cancer (NSCLC) Elderly Patients

Lead Sponsor:

Eli Lilly and Company

Conditions:

Non Small Cell Lung Cancer

Eligibility:

All Genders

70+ years

Phase:

PHASE2

Brief Summary

A phase II study to evaluate the efficacy and safety profile of the combination of Pemetrexed and Carboplatin in elderly patients with advanced non-small cell lung cancer

Eligibility Criteria

Inclusion

  • Pathologically confirmed Non Small Cell Lung Cancer Stage IIIb (not amenable to radiotherapy treatment) or Stage IV
  • No previous chemotherapy for lung cancer
  • Men and women \> or = 70 years
  • At least one uni-dimensionally measurable lesion (Response Evaluation Criteria In Solid Tumors \[RECIST\]criteria)
  • Eastern Cooperative Oncology Group (ECOG) Performance Status 0 to 1

Exclusion

  • Treatment within the last 30 days with a drug that has not received regulatory approval
  • Serious systemic disorders
  • Inability to discontinue administration of aspirin or anti-inflammatory non steroid
  • Concurrent administration of any other antitumor therapy
  • Brain metastasis

Key Trial Info

Start Date :

August 1 2006

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

November 1 2009

Estimated Enrollment :

62 Patients enrolled

Trial Details

Trial ID

NCT00350792

Start Date

August 1 2006

End Date

November 1 2009

Last Update

October 13 2010

Active Locations (7)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 2 (7 locations)

1

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Bobigny, France, 93009

2

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Brest, France, 29609

3

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Caen, France, 14076

4

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Le Mans, France, 72000